Mariela Segura

University of Montreal - Canada Author

Mariela Segura received her M.Sc. and Ph.D. from the Faculty of Medicine of the University of Montreal, where she became interested in host-pathogen interactions. During two post-doctoral trainings (Laval University and McGill Centre for the Study of Host Resistance) she acquired expertise on cellular biology and immunomodulation by parasites. Dr. Segura started her independent research career at the Faculty of Veterinary Medicine in 2007 after being granted an important career award. She is known for research in the areas of infectious diseases and the underlying innate and adaptive immune responses, with a particular focus on the interactions of encapsulated streptococci (such as Streptococcus suis and Group B Streptococcus) with the components of the immune system.

Segura’s laboratory applies multidisciplinary approaches, from biochemistry to cellular and molecular immunology, to dissect the role of bacterial capsular polysaccharides (CPSs) on the immunopathogenesis of the disease caused by pathogenic streptococci. An interconnected research axe seeks out vaccine development against Streptococcus suis, an emerging swine and human pathogen.

Segura’s research contributions have been recognized by over 30 prizes and distinctions, a few of which are the Canada Research Chair, the UNESCO-L’Oréal Canada for Women in Science Research Excellence Award; the ‘Zoetis’ Award of Excellence in Research; the ‘Fisher Award’ of the Canadian Society of Microbiologists, and the Women of Distinction Award in Science and Technology. Dr Segura is author or co-author of 127 total publications, including research articles, review articles and book chapters. She has contributed to the training of over 90 graduate and undergraduate students in her laboratory.

Updated CV 31-May-2019

Mariela Segura 58 Followers 2 Articles

Articles 2

Home

Intensification of animal food production and emergence of new production systems (such as Raised Without Antibiotics or organic systems) has resulted in emergence or re-emergence of pathogens. These new societal trends, together with the willing to reduce the use of antimicrobials in livestock productions, highlight the importance of improving existing vaccines and/or development of new vaccination strategies to fight against emerging or re-emerging pathogens.

HealthArticle

Streptococcus suis autogenous vaccines: what do we know?

In spite of decades of research on S. suis vaccines, autogenous bacterins are almost the only preventive strategy available that swine producers have access to, but which are their weak spots?

4 Like5 Comments

shareMy favorites

25-Jul-2022calavetCan multiple vaccinations in piglets (Circovirus, Mycoplasma Hyopneumonie, Prrs) compromise an immature immune system and decrease the innate immune response, for example against Natural Killer cells?

Home

Figure 1. Most important sequence types (STs) of Streptococcus suis serotype 2 as determined by multilocus sequence typing (MLST). ST1 serotype 2 strains are mostly associated with disease in both pigs (where data available) and humans in Europe, Asia, Africa and South America (Argentina). ST7, a single locus variant of ST1, is endemic to mainland China. The situation is different in North America, where few clinical ST1 cases of infection in pigs and only 1 human ST1 case has been described. Indeed, North American serotype 2 strains belong mainly to ST25 (human and pigs) and ST28 (pigs only). The latter ST is also associated with swine clinical cases in mainland China, Australia, Japan and Thailand. Interestingly, Japan and Thailand are the only countries also reporting ST28 human cases. Besides North America, human cases of ST25 have been reported in Australia and Thailand. Finally, ST20 is prevalent only in Europe (mostly in The Netherlands). In this figure, numbers (1, 20, 25, 28, 104) in the different hosts represent different STs (i.e. ST1, ST20, ST25, ST28, ST104) and each ST has been attributed with a different color. Figure was modified from: Segura M, Fittipaldi N, Calzas C, Gottschalk M. Critical Streptococcus suis virulence factors: Are they all really critical? Trends Microbiol. 2017; 25(7):585-599. doi: 10.1016/j.tim.2017.02.005, with copyright permission.

HealthArticle

Streptococcus suis: The search for a solution

Why is there no effective commercial vaccine against Streptococcus suis?

4 Like2 Comments

shareMy favorites

29-Jul-2019marcelo.gottschHello. From my side, it would be great to see these data...but attention, only data publised in peer reviewed articles in recognized journals and not internet articles or congress abstracts with studies performed by private companies having interest on such products must be shared.
If you have those, it will be nice to share them!!! thank you. Marcelo Gottschalk

Mariela Segura

Streptococcus suis autogenous vaccines: what do we know?

Streptococcus suis: The search for a solution

Zhou Lydia

DAVI LIOU

Tonisity

Lallemand

BASF